The aim of our study was to compare the time to conversion and the conversion rate within 90 min in patients with recent-onset atrial fibrillation treated with vernakalant or ibutilide.
Cardiome Pharma has announced the publication of results from an open label, single-center, randomized controlled study conducted by independent researchers...
Brinavess is indicated in adults for rapid conversion of recent onset atrial fibrillation to sinus rhythm -For non-surgery patients: atrial fibrillation ≤ 7 days duration -For post-cardiac surgery patients: atrial fibrillation ≤ 3 days duration
Cardiome Pharma Corp. announced that it has received a response from the FDA regarding the regulatory path for Brinavess (vernakalant...
Correvio Pharma has resubmitted a New Drug Application (NDA) to the US FDA seeking approval for Brinavess (vernakalant hydrochloride, IV),...
Merck & Co has returned the global marketing and development rights to Cardiome Pharma Corporation for both the intravenous and...
Merck Inc., ceases development of the oral formulation of anti arrhythmic vernakalant which it has licensed from Cardiome Pharma of...